Role of Perfusion CT in Pancreatic Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01703650|
Recruitment Status : Active, not recruiting
First Posted : October 10, 2012
Last Update Posted : December 12, 2019
The purpose of this study is
- to determine whether the perfusion parameters in the normal pancreas and the pancreas cancer (adenocarcinoma or neuroendocrine tumor) are different on perfusion CT
- to determine whether initial perfusion parameters as well as perfusion parameter change in pancreas adenocarcinoma before and after chemotherapy are different between chemotherapy response group (CR, PR according to RECIST 1.1) and non response group (SD, PD according to RECIST 1.1).
|Condition or disease||Intervention/treatment|
|Adenocarcinoma, Pancreas Neuroendocrine Carcinoma of Pancreas||Drug: iopromide Procedure: CT|
- Performance of preoperative perfusion CT for preoperative staging is assessed by comparing with operative finding and histologic disease staging
- Estimation of initial or change of pancreas cancer perfusion parameters and whether those can provide cut-off value for predicting response of chemotherapy in patients with pancreas adenocarcinoma
|Study Type :||Observational|
|Actual Enrollment :||48 participants|
|Official Title:||Evaluation of Diagnostic Efficacy of Perfusion CT Using Wide Detector for Staging and Response Prediction After Chemotherapy in Pancreatic Cancer|
|Actual Study Start Date :||November 2012|
|Actual Primary Completion Date :||December 2015|
|Estimated Study Completion Date :||September 2020|
Resectable pancreas cancer
patients with resectable pancreas adenocarcinoma or neuroendocrine tumor underwent perfusion CT after intravenous iopromide administration
Other Name: Ultravist® (370mgI/mL)
Locally advanced Pancreas cancer
Patients with locally advanced pancreas cancer underwent perfusion CT after intravenous iopromide administration before and after chemotherapy.
Other Name: Ultravist® (370mgI/mL)
- Evaluation of the correlation between the initial perfusion parameters of the tumor and response of the chemotherapy [ Time Frame: after 6 cycles of the planned chemotherapy ]Initial perfusion parameters (blood volume, blood flow and permeability) are compared between CTx-responder and non-responders after 6 cycle of the scheduled chemotherapy, using RECIST 1.1 criteria.
- Correlation between change of perfusion parameters and the chemotherapy response [ Time Frame: after 6 cycles of the chemotherapy ]Perfusion parameters (blood volume, blood flow, and permeability) change between initial perfusion CT and second perfusion CT (which is taken after 2 cycle of the CTx) are compared between CTx-responder and non-responder after finishing 6 cycles of CTx according to RECIST 1.1 criteria.
- Perfusion parameters among different pancreas tumors [ Time Frame: within 2 months after finishing enrollment ]Perfusion parameters (blood volume, blood flow and permeability) are compared among the different types of the pancreas tumors to investigate perfusion parameters can help characterization of the tumors.
- comparison of perfusion parameters among the pancreas tumors and parenchyma [ Time Frame: within three weeks before pancreas tumor surgery ]blood volume, blood flow and permeability are compared between the tumor and the pancreas parenchyma.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01703650
|Korea, Republic of|
|Seoul National University Hospital|
|Seoul, Korea, Republic of, 110-744|
|Principal Investigator:||Jeong Min Lee, MD, PhD||Seoul National University Hospital|